Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer.
Napolitano S, Woods M, Lee HM, De Falco V, Martini G, Della Corte CM, Martinelli E, Famiglietti V, Ciardiello D, Anderson A, Fowlkes NW, Villareal OE, Sorokin A, Kanikarla P, Coker O, Morris V, Altucci L, Tabernero J, Troiani T, Ciardiello F, Kopetz S. Napolitano S, et al. Among authors: anderson a. Clin Cancer Res. 2023 Jun 13;29(12):2299-2309. doi: 10.1158/1078-0432.CCR-22-3894. Clin Cancer Res. 2023. PMID: 37040395 Free PMC article.
Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts.
Kanikarla Marie P, Sorokin AV, Bitner LA, Aden R, Lam M, Manyam G, Woods MN, Anderson A, Capasso A, Fowlkes N, Overman MJ, Menter DG, Kopetz S. Kanikarla Marie P, et al. Among authors: anderson a. Front Oncol. 2022 Sep 21;12:994333. doi: 10.3389/fonc.2022.994333. eCollection 2022. Front Oncol. 2022. PMID: 36212401 Free PMC article.
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.
Serritella AV, Shevrin D, Heath EI, Wade JL, Martinez E, Anderson A, Schonhoft J, Chu YL, Karrison T, Stadler WM, Szmulewitz RZ. Serritella AV, et al. Among authors: anderson a. Clin Cancer Res. 2022 Apr 14;28(8):1549-1559. doi: 10.1158/1078-0432.CCR-21-4049. Clin Cancer Res. 2022. PMID: 35110415 Free PMC article. Clinical Trial.
Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer.
Chalfin HJ, Pramparo T, Mortazavi A, Niglio SA, Schonhoft JD, Jendrisak A, Chu YL, Richardson R, Krupa R, Anderson AKL, Wang Y, Dittamore R, Pal SK, Lara PN, Stein MN, Quinn DI, Steinberg SM, Cordes LM, Ley L, Mallek M, Sierra Ortiz O, Costello R, Cadena J, Diaz C, Gulley JL, Dahut WL, Streicher H, Wright JJ, Trepel JB, Bottaro DP, Apolo AB. Chalfin HJ, et al. Among authors: anderson akl. Clin Cancer Res. 2021 Mar 1;27(5):1391-1398. doi: 10.1158/1078-0432.CCR-20-2891. Epub 2020 Dec 1. Clin Cancer Res. 2021. PMID: 33262136 Free PMC article.
Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
Zhang B, Stewart CA, Wang Q, Cardnell RJ, Rocha P, Fujimoto J, Solis Soto LM, Wang R, Novegil V, Ansell P, He L, Fernandez L, Jendrisak A, Gilbertson C, Schonhoft JD, Byun J, Jones J, Anderson AKL, Aparicio A, Tran H, Negrao MV, Zhang J, Wang WL, Wistuba II, Wang J, Wenstrup R, Byers LA, Gay CM. Zhang B, et al. Among authors: anderson akl. Br J Cancer. 2022 Aug;127(3):569-576. doi: 10.1038/s41416-022-01811-9. Epub 2022 Apr 19. Br J Cancer. 2022. PMID: 35440668 Free PMC article.
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
Zhao JL, Antonarakis ES, Cheng HH, George DJ, Aggarwal R, Riedel E, Sumiyoshi T, Schonhoft JD, Anderson A, Mao N, Haywood S, Decker B, Curley T, Abida W, Feng FY, Knudsen K, Carver B, Lacouture ME, Wyatt AW, Rathkopf D. Zhao JL, et al. Among authors: anderson a. Br J Cancer. 2024 Jan;130(1):53-62. doi: 10.1038/s41416-023-02487-5. Epub 2023 Nov 18. Br J Cancer. 2024. PMID: 37980367 Free PMC article. Clinical Trial.
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.
Scher HI, Graf RP, Schreiber NA, Jayaram A, Winquist E, McLaughlin B, Lu D, Fleisher M, Orr S, Lowes L, Anderson A, Wang Y, Dittamore R, Allan AL, Attard G, Heller G. Scher HI, et al. Among authors: anderson a. JAMA Oncol. 2018 Sep 1;4(9):1179-1186. doi: 10.1001/jamaoncol.2018.1621. JAMA Oncol. 2018. PMID: 29955787 Free PMC article.
DNA-Regulated Multi-Protein Complement Control.
Ma Y, Winegar PH, Figg CA, Ramani N, Anderson AJ, Ngo K, Ahrens JF, Chellam NS, Kim YJ, Mirkin CA. Ma Y, et al. Among authors: anderson aj. J Am Chem Soc. 2024 Nov 21. doi: 10.1021/jacs.4c11315. Online ahead of print. J Am Chem Soc. 2024. PMID: 39569872
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine.
Modjarrad K, Che Y, Chen W, Wu H, Cadima CI, Muik A, Maddur MS, Tompkins KR, Martinez LT, Cai H, Ramos M, Mensah S, Cumbia B, Falcao L, McKeen AP, Chang JS, Fennell KF, Huynh KW, McLellan TJ, Sahasrabudhe PV, Chen W, Cerswell M, Garcia MA, Li S, Sharma R, Li W, Dizon KP, Duarte S, Gillett F, Smith R, Illenberger DM, Efferen KS, Vogel AB, Anderson AS, Şahin U, Swanson KA. Modjarrad K, et al. Among authors: anderson as. NPJ Vaccines. 2024 Nov 20;9(1):229. doi: 10.1038/s41541-024-01013-9. NPJ Vaccines. 2024. PMID: 39567521
6,124 results